{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T02:58:36Z","timestamp":1785466716220,"version":"3.56.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin J Gastroenterol"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s12328-026-02370-9","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T13:20:16Z","timestamp":1779888016000},"page":"969-975","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Long-term survival with multidisciplinary treatment including local and systemic treatment for germline BRCA2-positive pancreatic acinar cell carcinoma"],"prefix":"10.1007","volume":"19","author":[{"given":"Kazuhide","family":"Matsumoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4286-8804","authenticated-orcid":false,"given":"Nao","family":"Fujimori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeo","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatoshi","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keijiro","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Ikenaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Nakata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Aishima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinao","family":"Oda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,27]]},"reference":[{"key":"2370_CR1","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1097\/MPA.0000000000001718","volume":"50","author":"H Takahashi","year":"2021","unstructured":"Takahashi H, Ikeda M, Shiba S, et al. Multicenter retrospective analysis of chemotherapy for advanced pancreatic acinar cell carcinoma. Pancreas. 2021;50:77\u201382.","journal-title":"Pancreas"},{"key":"2370_CR2","doi-asserted-by":"publisher","first-page":"5827","DOI":"10.3748\/wjg.v28.i40.5827","volume":"28","author":"LF Calimano-Ramirez","year":"2022","unstructured":"Calimano-Ramirez LF, Daoud T, Gopireddy DR, et al. Pancreatic acinar cell carcinoma: a comprehensive review. World J Gastroenterol. 2022;28:5827\u201344.","journal-title":"World J Gastroenterol"},{"key":"2370_CR3","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1093\/jjco\/hyad176","volume":"54","author":"K Ikezawa","year":"2024","unstructured":"Ikezawa K, Urabe M, Kai Y, et al. Comprehensive review of pancreatic acinar cell carcinoma: epidemiology, diagnosis, molecular features and treatment. Jpn J Clin Oncol. 2024;54:271\u201381.","journal-title":"Jpn J Clin Oncol"},{"key":"2370_CR4","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/j.pan.2021.05.011","volume":"21","author":"V Sridharan","year":"2021","unstructured":"Sridharan V, Mino-Kenudson M, Cleary JM, et al. Pancreatic acinar cell carcinoma: a multi-center series on clinical characteristics and treatment outcomes. Pancreatology. 2021;21:1119\u201326.","journal-title":"Pancreatology"},{"key":"2370_CR5","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s00261-012-9868-4","volume":"38","author":"SP Raman","year":"2013","unstructured":"Raman SP, Hruban RH, Cameron JL, et al. Acinar cell carcinoma of the pancreas: computed tomography features\u2014a study of 15 patients. Abdom Imaging. 2013;38:137\u201343.","journal-title":"Abdom Imaging"},{"key":"2370_CR6","doi-asserted-by":"publisher","first-page":"726","DOI":"10.21037\/jgo-24-845","volume":"16","author":"S Sugata","year":"2025","unstructured":"Sugata S, Yamaguchi A, Kamada H, et al. Metastatic pancreatic acinar cell carcinoma with BRCA2 gene alternation resected after modified FORFIRINOX therapy: a case report and literature review. J Gastrointest Oncol. 2025;16:726\u201337.","journal-title":"J Gastrointest Oncol"},{"key":"2370_CR7","doi-asserted-by":"publisher","first-page":"3345","DOI":"10.1200\/JCO.24.00936","volume":"43","author":"A Ohba","year":"2025","unstructured":"Ohba A, Ozaka M, Mizusawa J, Hepatobiliary and Pancreatic Oncology Group of the Japan Clinical Oncology Group (JCOG-HBPOG), et al. Modified fluorouracil, leucovorin, irinotecan, and oxaliplatin or S-1, irinotecan, and oxaliplatin versus nab-paclitaxel\u2009+\u2009gemcitabine in metastatic or recurrent pancreatic cancer (GENERATE, JCOG1611): a randomized, open-label, phase II\/III trial. J Clin Oncol. 2025;43:3345\u201354.","journal-title":"J Clin Oncol"},{"key":"2370_CR8","doi-asserted-by":"publisher","first-page":"3355","DOI":"10.1200\/JCO-25-00436","volume":"43","author":"JJ Knox","year":"2025","unstructured":"Knox JJ, O\u2019Kane G, King D, et al. PASS-01: randomized phase II trial of modified FOLFIRINOX versus gemcitabine\/nab-paclitaxel and molecular correlatives for previously untreated metastatic pancreatic cancer. J Clin Oncol. 2025;43:3355\u201368.","journal-title":"J Clin Oncol"},{"key":"2370_CR9","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1007\/s12328-024-01983-2","volume":"17","author":"K Teramatsu","year":"2024","unstructured":"Teramatsu K, Fujimori N, Murakami M, et al. Pathological complete response with FOLFIRINOX therapy for recurrence of pancreatic acinar cell carcinoma. Clin J Gastroenterol. 2024;17:776\u201381.","journal-title":"Clin J Gastroenterol"},{"key":"2370_CR10","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1002\/jhbp.12181","volume":"32","author":"K Nakata","year":"2025","unstructured":"Nakata K, Miyasaka Y, Ishizawa T, et al. Patients with pancreatic cancer with synchronous liver oligometastasis show a significant long-term survival benefit from resection under specific conditions: a multicenter national cohort study. J Hepatobiliary Pancreat Sci. 2025;32:611\u20139.","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"2370_CR11","doi-asserted-by":"publisher","first-page":"5151","DOI":"10.1200\/JCO.23.00561","volume":"41","author":"D Mandelker","year":"2023","unstructured":"Mandelker D, Marra A, Zheng-Lin B, et al. Genomic profiling reveals germline predisposition and homologous recombination deficien cy in pancreatic acinar cell carcinoma. J Clin Oncol. 2023;41:5151\u201362.","journal-title":"J Clin Oncol"},{"key":"2370_CR12","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1245\/s10434-024-16331-4","volume":"32","author":"AB Blair","year":"2025","unstructured":"Blair AB, Radomski SN, Chou J, et al. Survival outcomes and genetic characteristics of resected pancreatic acinar cell carcinoma. Ann Surg Oncol. 2025;32:1869\u201378.","journal-title":"Ann Surg Oncol"},{"key":"2370_CR13","doi-asserted-by":"publisher","first-page":"3239","DOI":"10.1158\/1078-0432.CCR-20-0418","volume":"26","author":"W Park","year":"2020","unstructured":"Park W, Chen J, Chou JF, et al. Genomic methods identify homologous recombination deficiency in pancreas adenocarcinoma and optimize treatment selection. Clin Cancer Res. 2020;26:3239\u201347.","journal-title":"Clin Cancer Res"},{"key":"2370_CR14","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nature03445","volume":"434","author":"H Farmer","year":"2005","unstructured":"Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434:917\u201321.","journal-title":"Nature"},{"key":"2370_CR15","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1903387","volume":"381","author":"T Golan","year":"2019","unstructured":"Golan T, Hammel P, Reni M, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med. 2019;381:317\u201327.","journal-title":"N Engl J Med"},{"key":"2370_CR16","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1200\/JCO.19.02931","volume":"38","author":"EM O\u2019Reilly","year":"2020","unstructured":"O\u2019Reilly EM, Lee JW, Zalupski M, et al. Randomized, multicenter, phase II trial of gemcitabine and cisplatin with or without veliparib in patients with pancreas adenocarcinoma and a germline BRCA\/PALB2 mutation. J Clin Oncol. 2020;38:1378\u201388.","journal-title":"J Clin Oncol"},{"key":"2370_CR17","doi-asserted-by":"crossref","first-page":"e13338","DOI":"10.1097\/MD.0000000000013338","volume":"97","author":"RT Shroff","year":"2018","unstructured":"Shroff RT, Hendifar A, McWilliams RR, et al. Response of germline BRCA2-mutated advanced pancreatic acinar cell carcinoma to olaparib: a case report. Med (Baltim). 2018;97:e13338.","journal-title":"Med (Baltim)"},{"key":"2370_CR18","first-page":"1641","volume":"7","author":"J Zhang","year":"2019","unstructured":"Zhang J, Wang J, Dong Y, et al. Pancreatic acinar cell carcinoma is associated with BRCA2 germline mutation: a case report. World J Clin Cases. 2019;7:1641\u20137.","journal-title":"World J Clin Cases"},{"key":"2370_CR19","first-page":"e06187","volume":"10","author":"X Bian","year":"2022","unstructured":"Bian X, Wang Y, Xu J, et al. Prolonged response on olaparib maintenance in metastatic pancreatic acinar cell carcinoma in a germline BRCA2 mutation carrier. Clin Case Rep. 2022;10:e06187.","journal-title":"Clin Case Rep"},{"key":"2370_CR20","first-page":"e2300561","volume":"7","author":"J Lin","year":"2023","unstructured":"Lin J, Guo X, Ma Y, et al. Genomic profiling reveals germline predisposition and response of BRCA2-mutated advanced pancreatic acinar cell carcinoma to olaparib: a case report. JCO Precis Oncol. 2023;7:e2300561.","journal-title":"JCO Precis Oncol"},{"key":"2370_CR21","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s10689-024-00398-9","volume":"23","author":"D Matsubara","year":"2024","unstructured":"Matsubara D, Sakamoto Y, Sudo K, et al. The response of pancreatic acinar cell carcinoma to platinum and olaparib therapy in a germline BRCA2 variant carrier: case report and literature review. Fam Cancer. 2024;23:429\u201334.","journal-title":"Fam Cancer"},{"key":"2370_CR22","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s12328-022-01741-2","volume":"16","author":"K Okada","year":"2023","unstructured":"Okada K, Uemura K, Okamoto W, et al. Pathologic complete response following FOLFIRINOX and olaparib treatment for hepatic metastasized pancreatic ductal adenocarcinoma with a germline BRCA mutation. Clin J Gastroenterol. 2023;16:283\u20138.","journal-title":"Clin J Gastroenterol"},{"key":"2370_CR23","doi-asserted-by":"publisher","first-page":"1357233","DOI":"10.3389\/fonc.2024.1357233","volume":"14","author":"G Wu","year":"2024","unstructured":"Wu G, Fang Y, Bi D, et al. Case report: immunotherapy in rare high TMB pancreatic acinar carcinoma. Front Oncol. 2024;14:1357233.","journal-title":"Front Oncol"},{"key":"2370_CR24","doi-asserted-by":"publisher","first-page":"NP24","DOI":"10.1177\/0300891620980792","volume":"107","author":"H Xu","year":"2021","unstructured":"Xu H, Wang X, Zhou S, et al. Efficacy of chemotherapy combined with toripalimab in PD-L1-positive and high tumor mutation burden pancreatic acinar cell carcinoma: case report. Tumori. 2021;107:NP24\u20137.","journal-title":"Tumori"},{"key":"2370_CR25","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s00535-023-01986-9","volume":"58","author":"T Sakakida","year":"2023","unstructured":"Sakakida T, Ishikawa T, Doi T, et al. Genomic landscape and clinical features of rare subtypes of pancreatic cancer: analysis with the national database of Japan. J Gastroenterol. 2023;58:575\u201385.","journal-title":"J Gastroenterol"}],"container-title":["Clinical Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-026-02370-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12328-026-02370-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-026-02370-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T02:05:21Z","timestamp":1785463521000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12328-026-02370-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,27]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["2370"],"URL":"https:\/\/doi.org\/10.1007\/s12328-026-02370-9","relation":{},"ISSN":["1865-7257","1865-7265"],"issn-type":[{"value":"1865-7257","type":"print"},{"value":"1865-7265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,27]]},"assertion":[{"value":"26 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest. Kyushu University Hospital does not require approval from the ethics committee for the publication of this case report. The authors have obtained oral consent from the patient for publication, and documented the content in the medical record in accordance with the ethical guidelines of the Japanese Society of Gastroenterology.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}